FDA Approves Abbott's Dual-Energy TactiFlex Duo Catheter for Complex AFib
ABT sits 31% above its 52-week low of $81.97.
Summary
Abbott received FDA approval for its TactiFlex Duo Ablation Catheter, a dual-energy device combining pulsed field ablation and radiofrequency energy to treat complex atrial fibrillation. This is the company's fifth major electrophysiology approval in just over a year, strengthening its position in the fast-growing PFA market. The approval was supported by favorable safety and effectiveness data from the FlexPulse IDE study presented at ESC 2026. Commercial launch is expected in the coming weeks, adding a differentiated product to Abbott's cardiovascular portfolio.
At the time of this announcement, ABT was trading at $107.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $187.5B. The 52-week trading range was $81.97 to $137.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.